Company Encyclopedia
View More
name
Shenqi
600613.SH
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, tonic and sedative, cold and cough, anti-fungal, gynecology, and other treatment fields. Its products include prescription drugs and OTC products, including products include sodium cantharidate vitamin B6 injection, sodium cantharidin injection, loquat cough granules, strong loquat dew, loquat cough capsules, jinwu gutong capsules, coral ringworm net, jingwu capsules, quantianma capsules, yindan xintai pills, etc. The company was founded in 1990 and is based in Shanghai, China.
3.157 T
600613.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking160/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.66%C
    • Profit Margin3.31%C
    • Gross Margin49.36%B
  • Growth ScoreD
    • Revenue YoY-14.14%E
    • Net Profit YoY23.67%B
    • Total Assets YoY-3.90%D
    • Net Assets YoY-0.55%D
  • Cash ScoreC
    • Cash Flow Margin3021.37%A
    • OCF YoY-14.14%E
  • Operating ScoreB
    • Turnover0.6B
  • Debt ScoreA
    • Gearing Ratio21.93%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shenqi: Used the halted "Essential Drug Promotion Plan" project to extract sales expenses of 44.84 million yuan, multiple executives were issued warning letters

    Shenqi Pharmaceuticals misappropriated sales expenses of 44.84 million yuan due to the illegal use of the discontinued "Essential Drug Promotion Plan" project, resulting in incorrect information in the 2023 annual report. The Shanghai Securities Regulatory Bureau has ordered the company to rectify the situation and required a rectification report to be submitted within 30 days. Meanwhile, Chairman Zhang Tao, General Manager Feng Bin, and Chief Financial Officer Chen Zhimian were issued warning letters for their negligence

    Zhitong·
    SH
    600613
    -1.29%
    SH
    900904
    -1.68%
    Zhitong·
    SH
    600613
    -1.29%
    SH
    900904
    -1.68%

    Shanghai Shenqi Pharmaceutical received an administrative supervision measure decision from the Securities Regulatory Commission for information disclosure violations

    Shanghai Shenqi received an administrative supervision decision from the Shanghai Securities Regulatory Bureau for information disclosure violations. The company used the "Essential Drug Promotion Plan" to extract sales expenses, resulting in errors in the 2023 annual report information disclosure. The regulatory bureau required the company to rectify and submit a rectification report, while issuing warning letters to three senior executives. The company stated that it would actively rectify, standardize accounting treatment, and ensure that normal operations are not affected

    Zhitong·
    SH
    900904
    -1.68%
    SH
    600613
    -1.29%
    Zhitong·
    SH
    900904
    -1.68%
    SH
    600613
    -1.29%

    Shenqi: Net profit of 32.8081 million yuan in the first half of 2025, a year-on-year decrease of 13.29%

    Shenqi announced that in the first half of 2025, operating income was 961 million yuan, a year-on-year decrease of 13.47%; net profit was 32.8081 million yuan, a year-on-year decrease of 13.29%. The company will not distribute profits or increase capital during this reporting period

    Zhitong·
    SH
    900904
    -1.68%
    SH
    600613
    -1.29%
    Zhitong·
    SH
    900904
    -1.68%
    SH
    600613
    -1.29%

    Shenqi: Maijisi pledged 26.67 million shares and released 18.259 million shares

    Shenqi announced that shareholder Maijisi pledged 26.67 million shares and released 18.259 million shares. Maijisi holds 88.0019 million shares of the company, accounting for 16.48% of the total share capital. Currently, the remaining pledged shares are 63 million, accounting for 11.80% of the total share capital. The controlling shareholder Shenqi Holdings and its holding companies collectively hold 179 million shares, accounting for 33.45% of the total share capital, with a total of 123 million pledged shares, accounting for 23.11% of the total share capital

    Zhitong·
    SH
    600613
    -1.29%
    Zhitong·
    SH
    600613
    -1.29%

    Shareholder of Shenqi, Zhang Ya, intends to reduce holdings by no more than 1% of shares

    According to the Zhitong Finance APP, Shenqi announced that Zhang Ya, a concerted actor of the controlling shareholder, plans to reduce her holdings in the company by no more than 10.3047 million shares through centralized bidding and block trading due to personal funding needs, with a planned reduction ratio of 1%

    Zhitong·
    SH
    600613
    -1.29%
    Zhitong·
    SH
    600613
    -1.29%
    © 2025 Longbridge｜Disclaimer